Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2018

Open Access 01-12-2018 | Correspondence

Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting

Authors: P. Bruijning-Verhagen, J. A. P. van Dongen, J. D. M. Verberk, R. Pijnacker, R. D. van Gaalen, D. Klinkenberg, H. E. de Melker, M.-J. J. Mangen

Published in: BMC Medicine | Issue 1/2018

Login to get access

Abstract

Background and objective

Since 2013, a biennial rotavirus pattern has emerged in the Netherlands with alternating high and low endemic years and a nearly 50% reduction in rotavirus hospitalization rates overall, while infant rotavirus vaccination has remained below 1% throughout. As the rotavirus vaccination cost-effectiveness and risk-benefit ratio in high-income settings is highly influenced by the total rotavirus disease burden, we re-evaluated two infant vaccination strategies, taking into account this recent change in rotavirus epidemiology.

Methods

We used updated rotavirus disease burden estimates derived from (active) surveillance to evaluate (1) a targeted strategy with selective vaccination of infants with medical risk conditions (prematurity, low birth weight, or congenital conditions) and (2) universal vaccination including all infants. In addition, we added herd protection as well as vaccine-induced intussusception risk to our previous cost-effectiveness model. An age- and risk-group structured, discrete-time event, stochastic multi-cohort model of the Dutch pediatric population was used to estimate the costs and effects of each vaccination strategy.

Results

The targeted vaccination was cost-saving under all scenarios tested from both the healthcare payer and societal perspective at rotavirus vaccine market prices (€135/child). The cost-effectiveness ratio for universal vaccination was €51,277 at the assumed vaccine price of €75/child, using a societal perspective and 3% discount rates. Universal vaccination became cost-neutral at €32/child. At an assumed vaccine-induced intussusception rate of 1/50,000, an estimated 1707 hospitalizations and 21 fatal rotavirus cases were averted by targeted vaccination per vaccine-induced intussusception case. Applying universal vaccination, an additional 571 hospitalizations and <  1 additional rotavirus death were averted in healthy children per vaccine-induced intussusception case.

Conclusion

While universal infant rotavirus vaccination results in the highest reductions in the population burden of rotavirus, targeted vaccination should be considered as a cost-saving alternative with a favorable risk-benefit ratio for high-income settings where universal implementation is unfeasible because of budget restrictions, low rotavirus endemicity, and/or public acceptance.
Appendix
Available only for authorised users
Literature
1.
Hahne S, Hooiveld M, Vennema H, van Ginkel A, de Melker H, Wallinga J, van Pelt W, Bruijning-Verhagen P. Exceptionally low rotavirus incidence in the Netherlands in 2013/14 in the absence of rotavirus vaccination. Euro Surveill. 2014;19(43).
2.
Verberk JDM, Bruijning-Verhagen P, de Melker HE. Rotavirus in the Netherlands; background information for the Health Council. In: RIVM Report. Bilthoven: National Institute of Public Health and the Environment; 2017. p. 1–70.
3.
4.
Enserink R, Scholts R, Bruijning-Verhagen P, Duizer E, Vennema H, de Boer R, Kortbeek T, Roelfsema J, Smit H, Kooistra-Smid M, et al. High detection rates of enteropathogens in asymptomatic children attending day care. PLoS One. 2014;9(2):e89496.CrossRefPubMedPubMedCentral
5.
6.
van Gaalen RD, van de Kassteele J, Hahne SJM, Bruijning-Verhagen P, Wallinga J. Determinants of rotavirus transmission: a lag nonlinear time series analysis. Epidemiology. 2017;28(4):503–13.CrossRefPubMedPubMedCentral
7.
Braeckman T, Theeten H, Lernout T, Hens N, Roelants M, Hoppenbrouwers K, Van Damme P. Rotavirus vaccination coverage and adherence to recommended age among infants in Flanders (Belgium) in 2012. Euro Surveill. 2014;19(20:pii=20806)CrossRefPubMed
8.
Rieck T, Wichmann O, Siedler A. Aktuelles aus der KV-Impfsurveillance; Impfquoten der rotavirus-, Masern-, HPV- und Influenza-Impfung in Deutschland. Epidemiologisches Bulletin. 2017;2017(1)
9.
Public Health England. National rotavirus immunisation programme update: preliminary vaccine coverage for England, February 2016 to July 2016. In: Infection Report. vol. 10 Number 32: Health Protection Report; 2016.
10.
de Hoog MLA, Vesikari T, Giaquinto C, Huppertz HI, Martinon-Torres F, Bruijning-Verhagen P. Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC). Hum Vaccin Immunother. 2018;14(4):1027–34.CrossRefPubMedPubMedCentral
11.
Bruijning-Verhagen P, Mangen MJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, de Waal WJ, Bonten MJ. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med. 2013;11:112.CrossRefPubMedPubMedCentral
12.
de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinje J, van Leusden F, Bartelds AI, van Duynhoven YT. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol. 2001;154(7):666–74.CrossRefPubMed
13.
de Wit MA, Koopmans MP, Kortbeek LM, van Leeuwen NJ, Bartelds AI, van Duynhoven YT. Gastroenteritis in sentinel general practices, The Netherlands. Emerg Infect Dis. 2001;7(1):82–91.CrossRefPubMedPubMedCentral
14.
Bruijning-Verhagen P, Sankatsing V, Kunst A, van den Born C, Bleeker E, Thijsen S, Ijzerman EP, van der Velden VH, Bonten MJ. Rotavirus-related hospitalizations are responsible for high seasonal peaks in all-cause pediatric hospitalizations. Pediatr Infect Dis J. 2012;31(12):e244–9.CrossRefPubMed
15.
16.
Schurink-van’ t Klooster TM, de Melker HEE. The national immunisation programme in the Netherlands: surveillance and developments in 2015-2016. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu; 2016.
17.
Mangen MJ, van Duynhoven YT, Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine. 2010;28(14):2624–35.CrossRefPubMed
18.
van Dongen F, Schuurman R, Bonten MJM, Study-Group ObotR. Rotavirus hospitalizations in the absence of rotavirus vaccine in 2015–2016 in the Netherlands. In: 5th European Expert Meeting on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017. p. 85.
19.
20.
Marlow R, Finn A, Trotter C. Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK. Vaccine. 2015;33(39):5212–6.CrossRefPubMed
21.
Quee F, de Hoog MLA, Schuurman R, Bruijning-Verhagen P. A comparison of incidence, transmission and burden of norovirus and rotavirus infections among young families in the Netherlands. In: 5th European Expert Meeting on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017. p. 83–4.
22.
ZIN. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland (ZIN); 2015. Geactualiseerde versie 2015
23.
Prelog M, Gorth P, Zwazl I, Kleines M, Streng A, Zlamy M, Heinz-Erian P, Wiedermann U. Universal mass vaccination against rotavirus: indirect effects on rotavirus infections in neonates and unvaccinated young infants not eligible for vaccination. J Infect Dis. 2016;214(4):546–55.CrossRefPubMed
24.
Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, Brown D, Ramsay ME, Ladhani SN. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. J Infect Dis. 2016;213(2):243–9.CrossRefPubMed
25.
Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M. Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. Hum Vaccin Immunother. 2014;10(8):2255–66.CrossRefPubMedPubMedCentral
26.
Kaufman HW, Chen Z. Trends in laboratory rotavirus detection: 2003 to 2014. Pediatrics. 2016;138(4):e20161173.CrossRefPubMed
27.
Sabbe M, Berger N, Blommaert A, Ogunjimi B, Grammens T, Callens M, Van Herck K, Beutels P, Van Damme P, Bilcke J. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill. 2016;21
28.
Veldwijk J, Lambooij MS, Bruijning-Verhagen PC, Smit HA, de Wit GA. Parental preferences for rotavirus vaccination in young children: a discrete choice experiment. Vaccine. 2014;32(47):6277–83.CrossRefPubMed
29.
30.
Nederlandse Zorgautoriteit. Toedieningskosten per vaccinatie - H006: neventarief 0 tot 5 jarige - Nederlandse Zorgautoriteit Rekenstaat 2014 tariefbeschikking. Utrecht: Nederlandse Zorgautoriteit; 2014.
31.
Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ, Consensus Group on Dutch Rotavirus V. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health. 2011;11:462.CrossRefPubMedPubMedCentral
32.
Leino T, Ollgren J, Stromberg N, Elonsalo U. Evaluation of the intussusception risk after pentavalent rotavirus vaccination in Finnish infants. PLoS One. 2016;11(3):e0144812.CrossRefPubMedPubMedCentral
33.
Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. Vaccine. 2016;34(32):3684–9.CrossRefPubMed
34.
Rha B, Tate JE, Weintraub E, Haber P, Yen C, Patel M, Cortese MM, DeStefano F, Parashar UD. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines. 2014;13(11):1339–48.CrossRefPubMed
35.
Oberle D, Jenke AC, von Kries R, Mentzer D, Keller-Stanislawski B. Rotavirus vaccination: a risk factor for intussusception? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(2):234–41.CrossRefPubMed
36.
Palupi-Baroto R, Lee KJ, Carlin JB, Bines JE. Intussusception in Australia: epidemiology prior to the introduction of rotavirus vaccine. Aust N Z J Public Health. 2015;39(1):11–4.CrossRefPubMed
37.
Reyes JF, Wood JG, Beutels P, Macartney K, McIntyre P, Menzies R, Mealing N, Newall AT. Beyond expectations: post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine. 2017;35:345–52.CrossRefPubMed
38.
Mangen MJ, Bouwknegt M, Friesema IH, Haagsma JA, Kortbeek LM, Tariq L, Wilson M, van Pelt W, Havelaar AH. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2015;196:84–93.CrossRefPubMed
39.
Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
40.
41.
Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for costeffectiveness in health care health technology assessment (HTA). Brussels: Belgian Health Care Knowledge Centre; 2008.
42.
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7.CrossRefPubMed
43.
Parez N, Giaquinto C, Du Roure C, Martinon-Torres F, Spoulou V, Van Damme P, Vesikari T. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis. 2014;14(5):416–25.CrossRefPubMed
44.
Publique HCdlS. Infections à rotavirus : suspension des recommandations de vaccination des nourrissons [rotavirus infections; recommendation for infant vaccination suspended]. In: Avis et rapports de HCSP. Paris: Haut Conseil de la Sante Publique (HCSP); 2015. p. 1–5.
45.
Pitzer VE, Atkins KE, de Blasio BF, Van Effelterre T, Atchison CJ, Harris JP, Shim E, Galvani AP, Edmunds WJ, Viboud C, et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS One. 2012;7(8):e42320.CrossRefPubMedPubMedCentral
46.
47.
Global Health Data Exchange. Perinatal care in the Netherlands 2008. 2008.
48.
Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J. 2010;29(1):73–5.CrossRefPubMed
49.
Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P. An update to “The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe”. Vaccine. 2010;28(47):7457–9.CrossRefPubMed
50.
Friesema IH, Lugner AK, van Duynhoven YT, Group GEW. Costs of gastroenteritis in the Netherlands, with special attention for severe cases. Eur J Clin Microbiol Infect Dis. 2012;31(8):1895–900.CrossRefPubMed
51.
52.
Haagsma JA, Geenen PL, Ethelberg S, Fetsch A, Hansdotter F, Jansen A, Korsgaard H, O'Brien SJ, Scavia G, Spitznagel H, et al. Community incidence of pathogen-specific gastroenteritis: reconstructing the surveillance pyramid for seven pathogens in seven European Union member states. Epidemiol Infect. 2013;141(8):1625–39.CrossRefPubMed
53.
van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63(1):72–9.CrossRefPubMed
54.
(Statistiek) SNCBvd: Beroepsbevolking; kerncijfers naar geslacht en andere kenmerken 1996–2014. 13 Februar 2015 edn; 2015.
55.
Vesikari T, Dennehy P, Matson D, Itzler R, Dallas M, Goveia M, DiNubile M, Heaton P, Lawrence J, Ciarlet M. Efficacy of Rotateq®, the pentavalent rotavirus vaccine, between doses: potential benefits of early protection [abstract]. Arch Dis Child. 2008;93:pw 70.
56.
Vesikari T, Itzler R, Karvonen A, Korhonen T, Van DP, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 2009;28(3):345–51.CrossRefPubMed
57.
Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr. 2010;169(11):1379–86.CrossRefPubMedPubMedCentral
Metadata
Title
Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting
Authors
P. Bruijning-Verhagen
J. A. P. van Dongen
J. D. M. Verberk
R. Pijnacker
R. D. van Gaalen
D. Klinkenberg
H. E. de Melker
M.-J. J. Mangen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2018
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-018-1134-3

Other articles of this Issue 1/2018

BMC Medicine 1/2018 Go to the issue

Research article

Neighbourhood level real-time forecasting of dengue cases in tropical urban Singapore

Research article

Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals

Research article

Efficacy and safety of methylene blue in the treatment of malaria: a systematic review

Commentary

Guideline developers are not the only experts: Utilising the FRAM method in sepsis pathways

Research article

Sleep deficiency and motor vehicle crash risk in the general population: a prospective cohort study

Research article

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma